Equillium(US:EQ)2025-06-18 11:13EQ504 for Ulcerative Colitis - EQ504, an AhR modulator, is being developed for ulcerative colitis with topline Phase 1 data expected in the second half of 2026 [8] - In vivo experiments show that colonic delivery of EQ504 results in a greater than 25-fold increase in exposure in colon tissues compared to blood [57, 58] - Clinical remission rates with AhR modulation are approximately 50%, compared to 20%-30% with current therapeutics [69] - The ulcerative colitis market is expected to exceed $12 billion in annual worldwide sales by 2030 [74] Itolizumab for acute graft-versus-host disease (aGVHD) - The Phase 3 EQUATOR study of Itolizumab in aGVHD did not show improvement in Day 29 outcomes but achieved statistically significant benefit in longer-term outcomes [7] - In the EQUATOR study, 44.9% of patients in the Itolizumab group achieved complete response (CR) at Day 99, compared to 28.6% in the placebo group (p-value 0.0354) [133] - Itolizumab Complete Responders had a statistically significant Duration of Complete Response with a median of 336 days vs 72 days observed on placebo (p-value 0.0166) [135, 136] - Itolizumab demonstrated statistically significant Failure Free Survival with a median of 154 days vs 70 days observed on Placebo (p-value 0.0430) [139, 140] EQ302 for Gastrointestinal Indications - EQ302, an oral IL-15/21 inhibitor, is in the preclinical stage targeting gastrointestinal indications [7] - There are over 750,000 non-responsive celiac disease patients in the United States, representing a multi-billion dollar annual market opportunity [188] Financial Status - As of March 31, 2025, Equillium had $14.5 million in total cash and investments [92]